176655-56-4 Usage
Description
Hydroxy Ritonavir, also known as Ritonavir EP Impurity E, is a metabolite of Ritonavir (R535000), which is an HIV-1 protease inhibitor. It plays a significant role in the treatment of HIV and has recently gained attention for its potential applications in COVID-19-related research.
Uses
Used in Pharmaceutical Industry:
Hydroxy Ritonavir is used as an active pharmaceutical ingredient (API) for the treatment of HIV-1 infections. As a metabolite of Ritonavir, it contributes to the overall efficacy of the drug in inhibiting the replication of the virus, thus helping to manage the progression of the disease in patients.
Used in COVID-19 Research:
Hydroxy Ritonavir is used as a research compound in the context of COVID-19. Its potential applications in this area are being explored, as it may offer insights into the development of new treatments or therapies for the disease. The compound's role in HIV-1 protease inhibition makes it a promising candidate for further investigation into its possible effects on other viral infections, such as COVID-19.
Check Digit Verification of cas no
The CAS Registry Mumber 176655-56-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,7,6,6,5 and 5 respectively; the second part has 2 digits, 5 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 176655-56:
(8*1)+(7*7)+(6*6)+(5*6)+(4*5)+(3*5)+(2*5)+(1*6)=174
174 % 10 = 4
So 176655-56-4 is a valid CAS Registry Number.
176655-56-4Relevant articles and documents
Recombinant expression and characterization of novel P450s from Actinosynnema mirum
Schmitz, Lisa Marie,Hageneier, Felix,Rosenthal, Katrin,Busche, Tobias,Brandt, David,Kalinowski, J?rn,Lütz, Stephan
supporting information, (2021/06/16)
Cytochrome P450 monooxygenases (P450s) are the major contributor in the metabolism of xenobiotics, including therapeutic agents. Thus, P450s find broad application in the pharmaceutical industry to synthesize metabolites of new active pharmaceutical ingredients in order to evaluate toxicity and pharmacokinetics. As an alternative to human hepatic P450s, microbial P450s offer several advantages, such as an easier and more efficient heterologous expression as well as higher stability under process conditions. Recently, the wild-type strain Actinosynnema mirum has been reported to catalyze hydroxylation reactions with high activity on a broad range of substrates. In this study, one of these substrates, ritonavir, was used to analyze the transcriptional response of the wild-type strain. Analysis of the differential gene expression pattern allowed the assignment of genes potentially responsible for ritonavir conversion. Heterologous expression of these candidates and activity testing led to the identification of a novel P450 that efficiently converts ritonavir resembling the activity of the human CYP3A4.
